DOT1L and breast carcinoma: In addition, as shown in Fig. 3d and Supplementary Fig. 6d, treatment with the DOT1L inhibitors led to significant down-regulation of the pro-proliferation genes in the PAM50 gene set, which were found to be overexpressed in breast cancer and link to aggressiveness and poor prognosis of breast cancer [22].